METALLATION ENHANCEMENTS IN TUMOR-IMAGING AND PDT THERAPY
    81.
    发明申请
    METALLATION ENHANCEMENTS IN TUMOR-IMAGING AND PDT THERAPY 审中-公开
    肿瘤成像和PDT治疗中的金属增强

    公开(公告)号:US20140081015A1

    公开(公告)日:2014-03-20

    申请号:US14088983

    申请日:2013-11-25

    IPC分类号: A61K41/00 A61K49/00

    摘要: A compound in the form of a metallized tetrapyrollic photosensitizer linked to a fluorescent dye where the photosensitizer (PS), is linked by a structure that does not have detrimental radiation emittance or absorbing characteristics, to a fluorophore, usually a cyanine dye (CD). The photosensitizer in accordance the invention is a metallized analog of porphyrins, chlorins, purpurinimides, bacterio pupurinimides, phthalocyanines, expanded porphyrins, benzoporphyrin derivatives and purpurins. The fluorophore is usually a cyanine dye with variable substituents. And, A method for determining effectiveness of PDT by comparing proportion of STAT-3 monomer with crosslinked STAT-3 dimer after PDT where the relative proportion of STAT-3 monomer to crosslinked STAT-3 directly correlates to efficacy of the PDT.

    摘要翻译: 与荧光染料连接的金属四光柄光敏剂形式的化合物,其中光敏剂(PS)通过不具有有害辐射发射或吸收特性的结构连接到荧光团,通常为花青染料(CD)。 根据本发明的光敏剂是卟啉,二氢卟酚,紫嘌呤酰胺,细菌栀子酰胺,酞菁,膨胀卟啉,苯并卟啉衍生物和紫杉醇的金属化类似物。 荧光团通常是具有可变取代基的花青染料。 另外,通过比较PDT后STAT-3单体与交联的STAT-3二聚体的比例,其中STAT-3单体与交联的STAT-3的相对比例与PDT的功效直接相关,从而确定PDT有效性的方法。

    BIVALENT MULTIFUNCTIONAL LIGANDS TARGETING A[BETA] OLIGOMERS AS TREATMENT FOR ALZHEIMER'S DISEASE
    85.
    发明申请
    BIVALENT MULTIFUNCTIONAL LIGANDS TARGETING A[BETA] OLIGOMERS AS TREATMENT FOR ALZHEIMER'S DISEASE 有权
    将一种作为治疗阿尔茨海默病的[BETA]寡聚体的双重多功能配体

    公开(公告)号:US20130156705A1

    公开(公告)日:2013-06-20

    申请号:US13810826

    申请日:2011-07-14

    IPC分类号: C07J43/00 G01N33/68 A61K49/00

    摘要: Bivalent multifunctional Aβ oligomerization inhibitors (BMAOIs) that target multiple risk factors involved in Alzheimer's disease are provided. The BMAOIs are useful for the treatment and/or prevention of Alzheimer's disease, as well as for diagnostic imaging of Aβ plaques in brain tissue. The BMAOIs comprise i) an Aβ oligomer (ApO)-inhibitor moiety which may have antioxidant activity (e.g. curcumin, curcumin derivatives, curcumin hybrids, resveratrol, etc.); ii) a cell membrane/lipid raft (CM/LR) anchoring moiety (e.g. cholesterol, cholesterylamine, a steroid, etc.); and iii) a spacer or linker moiety that stably links i)

    摘要翻译: 提供了靶向涉及阿尔茨海默病的多种危险因素的二价多功能Aβ低聚抑制剂(BMAOI)。 BMAOI可用于治疗和/或预防阿尔茨海默病,以及用于脑组织中Abeta斑块的诊断成像。 BMAOI包含i)可具有抗氧化活性的Abeta寡聚物(ApO)抑制剂部分(例如姜黄素,姜黄素衍生物,姜黄素杂合物,白藜芦醇等); ii)细胞膜/脂筏(CM / LR)锚定部分(例如胆固醇,胆固醇胺,类固醇等); 和iii)稳定连接的间隔物或接头部分i)

    Diagnostic method for atherosclerosis
    86.
    发明授权
    Diagnostic method for atherosclerosis 有权
    动脉粥样硬化的诊断方法

    公开(公告)号:US08383354B2

    公开(公告)日:2013-02-26

    申请号:US13083121

    申请日:2011-04-08

    申请人: Philip S. Low

    发明人: Philip S. Low

    IPC分类号: G01N33/53

    摘要: The invention relates to a method of identifying/monitoring active atherosclerotic plaques associated with blood vessel walls wherein the plaques comprise activated macrophages having accessible binding sites for a ligand. The method comprises the steps of administering to a patient being evaluated for atherosclerosis an effective amount of a composition comprising a conjugate of a ligand and a chromophore capable of emitting light under predetermined conditions, allowing sufficient time for the ligand conjugate to bind to the activated macrophages, subjecting the blood vessels to the predetermined conditions using a catheter-based device, and identifying active plaques by detecting light emitted by the chromophore using a catheter-based device or by using an external imaging technique. The invention also relates to a similar method wherein a chemical moiety capable of emitting radiation is conjugated to the ligand.

    摘要翻译: 本发明涉及鉴定/监测与血管壁相关的活动性动脉粥样硬化斑块的方法,其中斑块包含具有可配位结合位点的活化巨噬细胞。 该方法包括以下步骤:向被评估动脉粥样硬化的患者施用有效量的包含配体和能够在预定条件下发光的发色团的缀合物的组合物,允许配体缀合物足够的时间结合活化的巨噬细胞 使用基于导管的装置对血管进行预定条件,并且使用基于导管的装置或通过使用外部成像技术检测由发色团发出的光来识别活性斑块。 本发明还涉及一种类似的方法,其中能够发射辐射的化学部分与配体缀合。

    METALLATION ENHANCEMENTS IN TUMOR-IMAGING AND PDT THERAPY
    89.
    发明申请
    METALLATION ENHANCEMENTS IN TUMOR-IMAGING AND PDT THERAPY 有权
    肿瘤成像和PDT治疗中的金属增强

    公开(公告)号:US20120097538A1

    公开(公告)日:2012-04-26

    申请号:US13168421

    申请日:2011-06-24

    摘要: A compound in the form of a metallized tetrpyrollic photosensizer linked to a fluorescent dye where the photosensitizer (PS), is linked by a structure that does not have detrimental radiation emmitance or absorbing characteristics, to a fluorophore, usually a cyanine dye (CD). The photosensitizer in accordance the invention is a metallized analog of porphyrins, chlorins, purpurinimides, bacterio pupurinimides, phthalocyanines, expanded porphyrins, benzoporphyrin derivatives and purpurins. The fluorophore is usually a cyanine dye with varaible substituents. And, A method for determining effectiveness of PDT by comparing proportion of STAT-3 monomer with crosslinked STAT-3 dimer after PDT where the relative proportion of STAT-3 monomer to crosslinked STAT-3 directly correlates to efficacy of the PDT.

    摘要翻译: 与荧光染料连接的金属化四层光敏剂形式的化合物,其中光敏剂(PS)通过不具有有害辐射发射或吸收特性的结构连接到荧光团,通常为花青染料(CD)。 根据本发明的光敏剂是卟啉,二氢卟酚,紫嘌呤酰胺,细菌栀子酰胺,酞菁,膨胀卟啉,苯并卟啉衍生物和紫杉醇的金属化类似物。 荧光团通常是具有可变取代基的花青染料。 另外,通过比较PDT后STAT-3单体与交联的STAT-3二聚体的比例,其中STAT-3单体与交联的STAT-3的相对比例与PDT的功效直接相关,从而确定PDT有效性的方法。

    FLUORESCENT CONTRAST AGENTS
    90.
    发明申请
    FLUORESCENT CONTRAST AGENTS 审中-公开
    荧光对比剂

    公开(公告)号:US20110318273A1

    公开(公告)日:2011-12-29

    申请号:US13183687

    申请日:2011-07-15

    申请人: HELGE TOLLESHAUG

    发明人: HELGE TOLLESHAUG

    IPC分类号: A61K49/00

    摘要: The invention relates to contrast agents for imaging of diseases associated with inflammations. More specifically the invention provides optical imaging contrast agents for imaging of activated leukocytes and methods for imaging of such. The contrast agent changes its fluorescent properties upon reaction with oxidants produced by the activated leukocytes.

    摘要翻译: 本发明涉及用于成像与炎症有关的疾病的造影剂。 更具体地,本发明提供了用于成像活化白细胞的光学成像造影剂及其成像方法。 与由活化的白细胞产生的氧化剂反应,造影剂改变其荧光性质。